Looking for the best immune‐checkpoint inhibitor in pre‐treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0215|142|6|1277-1284

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.142, Iss.6, 2018-03, pp. : 1277-1284

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PD‐1 inhibitor‐related pneumonitis in lymphoma patients treated with single‐agent pembrolizumab therapy

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 5, 2018-03 ,pp. : 752-755

John Wiley & Sons Inc

Access to resources Recommend Favorite

Combined Irinotecan and Oxaliplatin in Patients with Advanced Pre-Treated Pancreatic Cancer

By  

Oncology, Vol. 67, Iss. 2, 2004-10 ,pp. : 93-97

Karger

Access to resources Recommend Favorite

Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care

By  

Oncology, Vol. 93, Iss. 3, 2017-06 ,pp. : 164-176

Karger

Access to resources Recommend Favorite

A phase II study to determine the efficacy and safety of oral treosulfan in patients with advanced pre‐treated Ewing sarcoma ISRCTN11631773

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 1, 2015-01 ,pp. : 158-159

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab

By  

Oncology, Vol. 93, Iss. 1, 2017-04 ,pp. : 62-66

Karger

Access to resources Recommend Favorite